Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL

Journal of Immunology

Volumn 169, Issue 10, 2002, Pages 5696-5707

  Rubio Godoy, Verena ^a   Dutoit, Valérie ^a   Zhao, Yingdong ^a   Simon, Richard ^a   Guillaume, Philippe ^a   Houghten, Richard ^a   Romero, Pedro ^a   Cerottini, Jean Charles ^a   Pinilla, Clemencia ^a   Valmori, Danila ^a  

^a Hopital Orthopedique de la Suisse Romande   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NONHUMAN; PRIORITY JOURNAL;

EID: 0037111305     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.10.5696     Document Type: Article

References (34)

1. Davis, M. M., and P. J. Bjorkman. 1988. T-cell antigen receptor genes and T-cell recognition. Nature 334:395.
2. + T cells in the thymus. Cell 73:1041.
3. Alam, S. M., P. J. Travers, J. L. Wung, W. Nasholds, S. Redpath, S. C. Jameson, and N. R. Gascoigne. 1996. T-cell-receptor affinity and thymocyte positive selection. Nature 381:616.
4. Goldrath, A. W., and M. J. Bevan. 1999. Selecting and maintaining a diverse T-cell repertoire. Nature 402:255.
5. Dietrich, P. Y., P. R. Walker, A. L. Quiquerez, G. Perrin, V. Dutoit, D. Lienard, P. Guillaume, J. C. Cerottini, P. Romero, and D. Valmori. 2001. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res. 61:2047.
6. Mason, D. 1998. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 19:395.
7. Baker, B. M., S. J. Gagnon, W. E. Biddison, and D. C. Wiley. 2000. Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: Implications for TCR signaling. Immunity 13:475.
8. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160:1750.
9. Madden, D. R., D. N. Garboczi, and D. C. Wiley. 1993. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 75:693.
10. Loftus, D. J., Y. Chen, D. G. Covell, V. H. Engelhard, and E. Appella. 1997. Differential contact of disparate class 1/peptide complexes as the basis for epitope cross-recognition by a single T cell receptor. J. Immunol. 158:3651.
11. Hemmer, B., M. Vergelli, B. Gran, N. Ling, P. Conlon, C. Pinilla, R. Houghten, H. F. McFarland, and R. Martin. 1998. Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J. Immunol. 160:3631.
12. Wilson, C. S., J. M. Moser, J. D. Altman, P. E. Jensen, and A. E. Lukacher. 1999. Cross-recognition of two middle T protein epitopes by immunodominant polyoma virus-specific CTL. J. Immunol. 162:3933.
13. Hemmer, B., M. Vergelli, C. Pinilla, R. Houghten, and R. Martin. 1998. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol. Today 19:163.
14. Zhao, Y., B. Gran, C. Pinilla, S. Markovic-Plese, B. Hemmer, A. Tzou, L. W. Whitney, W. E. Biddison, R. Martin, and R. Simon. 2001. Combinatorial peptide libraries and biometric score matrices permit the quantitative analysis of specific and degenerate interactions between clonotypic TCR and MHC peptide ligands. J. Immunol. 167:2130.
15. Coulie, P. G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
16. Pinilla, C., V. Rubio-Godoy, V. Dutoit, P. Guillaume, R. Simon, Y. Zhao, R. A. Houghten, J. C. Cerottini, P. Romero, and D. Valmori. 2001. Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes. Cancer Res. 61:5.153.
17. Valmori, D., N. Gervois, D. Rimoldi, J. F. Fonteneau, A. Bonelo, D. Lienard, L. Rivoltini, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. [Published erratum appears in 1999 Immunol. 163:1093.] J. Immunol. 161:6956.
18. Valmori, D., M. J. Pittet, D. Rimoldi, D. Lienard, R. Dunbar, V. Cerundolo, F. Lejeune, J. C. Cerottini, and P. Romero. 1999. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res. 59:2167.
19. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D, Lienard, J. C, Cerottini, and V, Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class 1 major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641.
20. + cytolytic T-lymphocyte clone. Cancer Res. 62:2058.
21. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163.
22. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A. Steinle, T. Wolfel, D. Lienard, V. Brichard, et al. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159:2366.
23. + T cells in melanoma patients. J. Immunol. 165:533.
24. Valmori, D., V. Dutoit, V. Schnuriger, A. L. Quiquerez, M. J. Pittet, P. Guillaume, V. Rubio-Godoy, P. R. Walker, D. Rimoldi, D. Lienard, et al. 2002. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J. Immunol. 168:4231.
25. + T cells in humans. J. Exp. Med. 196:207.
26. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190:705.
27. Valmori, D., J. F. Fonteneau, S. Valitutti, N. Gervois, R. Dunbar, D. Lienard, D. Rimoldi, V. Cerundolo, F. Jotereau, J. C. Cerottini, et al. 1999. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int. Immunol. 11:1971.
28. Garboczi, D. N., P. Ghosh, U. Utz, Q. R. Fan, W. E. Biddison, and D. C. Wiley. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134.
29. Garcia, K. C., M. Degano, R. L. Stanfield, A. Brunmark. M. R. Jackson, P. A. Peterson, L. Teyton, and I. A. Wilson. 1996. An αβ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 274:209.
30. 27-35. J. Exp. Med. 184:647.
31. Rubio-Godoy, V., M. Ayyoub, V. Dutoit, C. Servis, A. Schink, D. Rimoldi, J. C. Cerottini, R. Simon, Y. Zhao, R. Houghten, et al. 2002. Combinatorial peptide library based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity. Eur. J. Immunol. 32:2292.
32. Nordlund, J. J., J. M. Kirkwood, B. M. Forget, G. Milton, D. M. Albert, and A. B. Lerner. 1983. Vitiligo in patients with metastatic melanoma: A good prognostic sign. J. Am. Acad. Dermatol. 9:689.
33. Duhra, P., and A. Ilchyshyn. 1991. Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin. Exp. Dermatol. 16:303.
34. Ogg, G. S., P. R. Dunbar, P. Romero, J. L. Chen, and V. Cerundolo. 1998. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in auto-immune vitiligo. J. Exp. Med. 188:1203.